Sartorius reported strong Q3 19 numbers. Revenue was up by 14.7% – driven by Bioprocess Solutions (+17%) and supported by Lab Products and Services (+8.3%). EBITDA came in at €123.7m (margin +30bp to 26.8%). Management upgraded its FY 19 top-line growth guidance to the upper end of the earlier 10-14% range while re-iterating its EBITDA margin expectations (slightly above 27%). The company also announced the acquisition of parts of Danaher’s life science business. Following th
23 Oct 2019
Solid Q3 leads to another guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid Q3 leads to another guidance upgrade
Sartorius AG (0NIQ:LON) | 0 0 0.0% | Mkt Cap: 10,352m
- Published:
23 Oct 2019 -
Author:
Virendra Chauhan -
Pages:
3
Sartorius reported strong Q3 19 numbers. Revenue was up by 14.7% – driven by Bioprocess Solutions (+17%) and supported by Lab Products and Services (+8.3%). EBITDA came in at €123.7m (margin +30bp to 26.8%). Management upgraded its FY 19 top-line growth guidance to the upper end of the earlier 10-14% range while re-iterating its EBITDA margin expectations (slightly above 27%). The company also announced the acquisition of parts of Danaher’s life science business. Following th